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Abstract
Background: International cohort studies have shown that antiretroviral treatment (ART) has improved survival of
HIV-infected individuals. National population based studies of HIV mortality exist in industrialized settings but few
have been presented from developing countries. Our objective was to investigate on a population basis, the
regional situation regarding HIV mortality and trends in Latin America (LA) in the context of adoption of public
ART policies and gender differences.
Methods: Cause of death data from vital statistics registries from 1996 to 2007 with “good” or “average” quality of
mortality data were examined. Standardized mortality rates and Poisson regression models by country were
developed and differences among countries assessed to identify patterns of HIV mortality over time occurring in
Latin America.
Results: Standardized HIV mortality following the adoption of public ART policies was highest in Panama and El
Salvador and lowest in Chile. During the study period, three overall patterns were identified in HIV mortality trends-
following the adoption of the free ART public policies; a remarkable decrement, a remarkable increment and a
slight increment. HIV mortality was consistently higher in males compared to females. Mean age of death
attributable to HIV increased in the majority of countries over the study period.
Conclusions: Vital statistics registries provide valuable information on HIV mortality in LA. While the introduction of
national policies for free ART provision has coincided with declines in population-level HIV mortality and increasing
age of death in some countries, in others HIV mortality has increased. Barriers to effective ART implementation and
uptake in the context of free ART public provision policies should be further investigated.
Background
The worldwide scale-up of antiretroviral therapy (ART)
has substantially improved survival and quality of life of
HIV-infected individuals. There is clear evidence that
mortality associated with AIDS as well as incidence of
AIDS-defining clinical conditions have fallen drastically
in industrialized countries that provide good access to
ART, such as the United States and Western European
countries [1-9]. Improvement in survival among AIDS
patients in developing countries has also been documen-
ted [10-12].
Despite increases in ART coverage to more than 4
million people in low- and middle-income countries by
2008 [13], HIV/AIDS has continued to be the fourth
most frequent cause of death in low income countries
[14]. Greater evidence is needed to better understand
the impact of the HIV epidemic and AIDS mortality fol-
lowing the introduction of ART.
Models for the HIV epidemic for Latin America (LA)
have shown a 21% increment in HIV annual mortality
between 2001 and 2004 and a drop to 16% in the year
2008 [15]. The decline between 2004 and 2008 has been
associated with increased availability and access to ART
throughout the Latin American region [15]. Yet, differ-
ences both among and within countries exist and treat-
ment coverage continues to be suboptimal in many
areas [16-18].
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tries have shown improvements in survival among
patients on ART [16,19]. In addition to HIV cohorts,
the study of vital registration data and reported mortal-
ity due to HIV/AIDS can provide insight regarding the
impact of HIV programs and policies at the population
level. Several countries in LA have conducted trend ana-
lyses of reported HIV mortality [20-31]. Here, we pro-
vide a regional analysis of HIV/AIDS mortality between
1996 and 2007, in the context of adoption of public
policies marking commencement of national provision
of ART between 1997 and 2004 in Latin American
countries with mortality records classified from average
to good quality. The objective was to analyze patterns
and trends in population-level mortality due to HIV/
AIDS among Latin American countries and compare
age-adjusted trends in mortality by sex.
Methods
This study draws on national vital registration mortality
data from Latin American countries for the available
years at the time of analysis using ICD10-coded data.
Only countries with “good” or “average” quality mortal-
ity registration data, according to the Pan American
Health Organization (PAHO) [32,33], were examined.
The classification for quality of mortality data relies on
a composite index based on the proportion of estimated
mortality under-registration and on the proportion of
deaths assigned to ill-defined and unknown causes. The
index was calculated for each country for the years 2003
to 2005, using the formula:
0.7×

% under registration of mortality

+0.3×(proportion of deaths of ill-deﬁned and unknown causes)
Countries were classified according to the value of the
index as having good quality (index ≤ 10%; Argentina,
Chile, Cost Rica, Guatemala, Mexico, Uruguay, and
Venezuela), average quality (11 to 20%; Brazil, Colom-
bia, Ecuador, El Salvador, and Panama), poor or very
poor quality ( 2 1t o4 0 % ,a n d>4 1 % ;N i c a r a g u a ,P e r u ,
Bolivia, Paraguay) data. No data was available for Hon-
duras and Guatemala was excluded because mortality
data was only available for the years 2005 and 2006.
Data sources and analysis
HIV/AIDS mortality data were obtained from the
PAHO database of reported mortality data [34] by cause
of death, age and sex. This information is produced by
national vital statistics departments, registries and minis-
tries of health and is reported annually by ministries of
health in LA to PAHO.
Crude mortality rates were calculated using the 2006
population estimates of the Division of Population of
the United Nations as denominators. The numerators
were the number of registered deaths for which the
underlying cause of death was “Acquired Immunodefi-
ciency Syndrome (AIDS)”, corresponding to ICD-10
codes: B20 to B24. No correction for mortality under-
registration or redistribution of causes was undertaken.
Poisson regression models were fitted by country to
obtain adjusted rate ratios by year, age group and sex,
using as baseline the year of commencement of public
provision of antiretroviral therapy, as well as to test dif-
ferences in time trends. When statistically significant
differences in trends by sex were detected, using likeli-
hood ratio tests, separate models for men and women
were fit and tendencies by sex were presented sepa-
rately. Processing and analysis of the data was carried
out using STATA SE 11.0 for Windows (Stata Corpora-
tion, College Station TX, USA).
Age group categories used for standardization of death
rates and for regression models were 0 to 4, 5 to 14, 15
to 24, 25 to 44, 45 to 64, and 65 years and over. Mean
age at time of death was determined using mean mid-
age-group data at time of death. These data were avail-
able in aggregated one-year age groups from 1 to 4
years in age and in five-year age groups thereafter. Com-
parisons of means were conducted using analysis of var-
iance (ANOVA) when comparing by sex and year. Cases
of unknown sex or age were included for the analysis of
total mortality rates.
In 1996, Brazil became the first developing country to
commit to and implement policies to provide free and
universal access to highly active antiretroviral therapy
(ART). Currently all countries in Latin America have
established public policies that provide ART free of
charge within designated publicly financed health service
facilities. For purposes of the study, we defined the year
when this occurred as the year when the national gov-
ernment first published a document delineating a
national policy of provision of free of charge ART to all
patients in need of treatment [35-39]. All countries
included in the study had national ART guidelines that
defined first-line regimens. The level of implementation
of national guidelines is thought to be uneven within
and among countries due to treatment costs, barriers to
HIV testing and limitations in health services capacity in
each country [40], yet is not known with precision.
National estimates of ART coverage between 2004 and
2009 appear in Table 1.
To compare HIV mortality trends among countries,
age-standardized mortality rates were calculated for
each year using the direct standardization method. The
sum of the population estimates for the year 2000 from
the Division of Population of the United Nations for the
countries included in the study was used as the refer-
ence population. The ratio of standardized mortality
rates for men relative to women adjusted for age was
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marize differences by sex.
Results
HIV/AIDS mortality rates were analyzed for the years
1996 to 2007. Most countries had available data for the
years 1997 to 2006. The mean mortality follow up was
9.9 years, with a range of 7 years (for Uruguay) to 12
years (for Brazil) (Table 1). The mean crude HIV mor-
tality rate over the study period was 5.3 per 100,000
population (95% CI 4.7-5.8) with a range of 3.0 to 13.1
per 100,000 across countries.
a
Mortality patterns and trends
Age and sex-standardized mortality rates in the period
prior to the adoption of public ART policies in the
different countries ranged from 2.2 to 15.6 deaths per
100,000 (mean 5.7, CI 4.1-7.2). In comparison, after the
ART public policy adoption the rates were 2.5 to 14.0
(mean 5.1, CI 4.5-5.7; p = 0.4). During the study periods
of 1999 to 2004 and 2006, Panama, followed by El Sal-
vador, presented the highest HIV mortality rates and
Chile the lowest. Standardization did not alter the HIV
mortality rates substantially. HIV mortality trends
appear to follow three patterns. About half of the coun-
tries present a remarkable decrement in HIV mortality
rates after the initiation of public provision of ART
(Argentina, Brazil, Chile, Costa Rica and El Salvador). In
Panama, the mortality rate decreased after the official
start date of public ART provision, but this reduction
did not achieve statistical significance. A second group
of countries (Colombia and Ecuador) presented a
Table 1 Population, number and HIV prevalence, ART coverage, and establishment of national policy for public
provision of ART (year), % of male deaths, HIV mortality rate ratios in men compared to women 1996-2007
Country Country
population
2009 (in
thousands)
Number of
persons living
with HIV:
Total/females
2001/2009
15-49 years old
estimated HIV
prevalence (%)
2001/2009
Estimated ART
coverage (%)
2004**
Year of
National ART
Policy
% male
deaths
Male-female HIV
mortality rate ratio
***
95% confidence
interval
Argentina 40,666 110000/36000 0.4/0.5 88 1997
1 74.0% 2.8 (2.7-2.9)
Brazil 195424 NA [0.3-0.5]/[0.3-0.6]¥ [70-95] ¥ 1996
2 70.1% 2.3 (2.3-2.4)
Chile 17134 40000/12000 0.3/0.4 72 2001
3 87.45% 6.9 (6.3-7.6)
Colombia 46299 160000/50000 0.8/0.5 20 1999
4 81.1% 4.3 (4.1-4.4)
Costa
Rica
4641 9800/2800 0.2/0.3 95 1997
5 84.8% 5.6 (4.8-6.4)
Ecuador 13772 37000/11000 0.5/0.4 10 2003
6 82.6% 4.7 (4.4-5.1)
El
Salvador
6193 34000/11000 0.8/0.8 23 2004
7 72.3% 2.6 (2.4-2.8)
Mexico 110647 220000/59000 0.3/0.3 46 2003
8 83.8% 5.2 (5.0-5.3)
Panama 3507 20000/6300 1.4/0.9 25 2001
9 75.0% 3.0 (2.8-3.2)
Uruguay 3373 9900/3100 0.4/0.5 95 1997
10 76.4% 3.2 (2.8-3.8)
Venezuela 29044 NA NA NA 1999
11 81.7% 4.5 (4.3-4.7)
Source column #1: UN Population projections. Source columns #3, 4 and 5: UNAIDS. Report on the global AIDS epidemic 2010, Geneva, 2010
* Data unavailable for: Panama for 2005; Uruguay for 2002.
ART: antiretroviral therapy
IRR = Incidence rate ratio
** ART coverage using as numerator persons reported on treatment at end of reporting year and denominator the estimated treatment need criteria CD4 < 200.
1. National UNGASS report-Argentina, 2008
2. National UNGASS report -Brasil, 2008
3. National UNGASS report -Chile, 2008
4. OPS/ORAS/ONUSIDA Análisis de la situación de VIH en la subregión andina, 2003-2008, March 2007.
5. National UNGASS report -Costa Rica, 2008
6. National UNGASS report -Ecuador, 2008
7. National UNGASS report -El Salvador, 2008
8. National UNGASS report -México, 2008
9. National UNGASS report -Panamá, 2008
10. Ministerio de Salud Publica. Resolution Nª171/1997, that includes universal access to ARV drugs to all AIDS patients. Uruguay 1997
11. PAHO. Legislation and milestones on access to treatment in Latin America and the Caribbean. Pan American Health Organization. August 2003. Last accessed
30/1/2010. Available at http://www.paho.org/Spanish/AD/FCH/AI/acceso-arv-06.doc
*** Ratios adjusted for age groups and over time for the study period, p < 0.000 for all rate ratios.
NA: Not available
¥: point estimate unavailable for Brazil, modelled uncertainty interval provided
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Finally, Mexico, Venezuela and Uruguay had varied
trends in rate ratios with an overall increasing mortality
pattern after adopting the public ART policies (Figure
1). Increase in male and female mortality rates, relative
to the year of establishment of free ART public policies,
varied from 12% to 39% among countries with an
increasing trend, and declined by 15% to 54% for those
with a decreasing trend.
HIV mortality rates by country were much higher in
males when compared to females over the study per-
iod, comprising 75% of total HIV/AIDS deaths and
with rate ratios from 2.3 to 6.9 relative to females
across countries (Table 1) (Figure 2). When evaluating
Figure 1 Sex and age-adjusted HIV mortality rate per 100,000 population.
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ferences were detected in Argentina, Brazil, Costa Rica,
El Salvador, Colombia, Mexico and Venezuela (p <
0.001), not so in Chile, Ecuador, Panama and Uruguay.
(Tables 2 and 3).
In Argentina, Brazil, Costa Rica and El Salvador, HIV
mortality rates among males decreased significantly after
the public provision of ART (p < 0.000) (Tables 2 and
3). In contrast, HIV mortality trends among women in
those countries either show no decrease, such as in the
Figure 2 Age-adjusted HIV mortality rate per 100,000 by sex in Latin American countries, 1996-2007. Note at bottom of figure: Dot on
trends lines mark start year of national provision of antiretroviral treatment.
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Page 5 of 11Table 2 Age-Adjusted HIV mortality rate ratios 1996-2007 among countries with significant differences in time trend by sex
Argentina Brazil Colombia Costa Rica El Salvador Mexico Venezuela
F
(95% CI)
M
(95% CI)
F
(95% CI)
M
(95% CI)
F
(95% CI)
M
(95% CI)
F
(95% CI)
M
(95% CI)
F
(95% CI)
M
(95% CI)
F
(95% CI)
M
(95% CI)
F
(95% CI)
1996 – – 1.00 1.00 –
–
–
–
––––
–
–
–
– 0.80
(0.73-0.87)
0.52
(0.41-0.65)
1997 1.00 1.00 0.78
(0.76-0.80)
0.87
(0.83-0.91)
0.87
(0.81-0.94)
0.73
(0.61-0.88)
1.00 1.00 0.53
(0.45-0.63)
0.34
(0.25-0.46)
–
–
– 0.91
(0.83-0.99)
0.72
(0.58-0.89)
1998 0.93
(0.86-1.0)
0.96
(0.84-1.1)
0.69
(0.67-0.71)
0.81
(0.77-0.85)
0.81
(0.75-0.88)
0.89
(0.75-1.07)
0.73
(0.57-0.93)
0.68
(0.35-1.39)
0.66
(0.57-0.78)
0.44
(0.34-0.59)
0.91
(0.87-0.95)
0.81
(0.73-0.90)
0.91
(0.84-0.99)
0.86
(0.70-1.05)
1999 0.81
(0.75-0.87)
0.87
(0.76-1.0)
0.67
(0.65-0.69)
0.79
(0.75-0.83)
1.00 1.00 0.71
(0.55-0.90)
0.67
(0.35-1.39)
0.71
(0.61-0.83)
0.63
(0.49-0.80)
0.94
(0.90-0.98)
0.80
(0.72-0.89)
1.00 1.00
2000 0.83
(0.77-0.90)
0.80
(0.70-0.92)
0.68
(0.66-0.70)
0.83
(0.80-0.87)
1.10
(1.02-1.18)
1.23
(1.05-1.45)
0.60
(0.47-0.78)
0.98
(0.57-1.94)
1.03
(0.90-1.19)
0.98
(0.79-1.22)
0.93
(0.89-0.98)
0.84
(0.76-0.94)
1.05
(0.96-1.14)
0.98
(0.81-1.18)
2001 0.81
(0.75-0.87)
0.87
(0.76-1.0)
0.67
(0.65-0.69)
0.90
(0.86-0.94)
1.20
(1.12-1.29)
1.39
(1.18-1.62)
0.74
(0.58-0.94)
0.86
(0.51-1.78)
0.98
(0.85-1.13)
0.91
(0.73-1.14)
0.94
(0.90-1.0)
0.92
(0.83-1.02)
0.93
(0.85-1.02)
1.06
(0.89-1.28)
2002 0.84
(0.78-0.91)
0.88
(0.77-1.01)
0.68
(0.65-0.69)
0.91
(0.87-0.95)
1.18
(1.10-1.27)
1.54
(1.32-1.79)
0.69
(0.54-0.88)
0.49
(0.26-1.15)
0.93
(0.81-1.07)
0.94
(0.76-1.18)
0.98
(0.93-1.02)
0.93
(0.84-1.03)
0.88
(0.81-0.96)
1.25
(1.04-1.49)
2003 0.86
(0.79-0.93)
0.95
(0.83-1.1)
0.69
(0.67-0.71)
0.95
(0.90-1.0)
1.21
(1.13-1.30)
1.8
(1.55-2.09)
0.75
(0.59-0.95)
1.01
(0.63-2.10)
1.11
(0.97-1.28)
0.93
(0.74-1.16)
1.00 1.00 0.99
(0.91-1.10)
1.18
(0.98-1.41)
2004 0.78
(0.72-0.85)
0.90
(0.79-1.04)
0.67
(0.65-0.69)
0.93
(0.89-0.98)
1.33
(1.24-1.42)
1.95
(1.68-2.26)
0.60
(0.47-0.78)
1.16
(0.76-2.40)
1.00 1.00 1.02
(0.97-1.06)
1.07
(0.97-1.18)
1.06
(0.97-1.16)
1.42
(1.19-1.69)
2005 0.69
(0.63-0.75)
0.87
(0.76-1.0)
0.66
(0.64-0.68)
0.98
(0.93-1.02)
1.28
(1.19-1.37)
1.75
(1.50-2.03)
0.69
(0.54-0.88)
0.76
(0.48-1.70)
0.77
(0.67-0.90)
0.98
(0.78-1.21)
1.01
(0.96-1.05)
1.05
(0.95-1.16)
1.11
(1.02-1.21)
1.58
(1.33-1.88)
2006 0.75
(0.69-0.81)
0.89
(0.77-1.01)
0.66 (0.64-.68) 0.97
(0.93-1.02)
1.28
(1.20-1.37)
1.86
(1.60-2.16)
0.71
(0.56-0.91)
1.20
(0.82-2.56)
0.84
(0.72-0.97)
0.79
(0.62-0.99)
1.07
(1.02-1.11)
1.12
(1.02-1.24)
—–
2007 0.74
(0.68-.80)
0.99
(0.87-1.13)
0.68
(0.66-0.70)
0.99
(0.95-1.04)
–
–
–
–
0.62
(0.48-0.80)
0.98
(0.66-2.17)
–
–
1.10
(1.04-1.14)
1.22
(1.12-1.34)
—–
HIV mortality rate ratios are calculated relative to the year of commencement of large-scale public provision of ART
* Countries present in this table have statistically significant interactions between sex and year for HIV mortality.
Models adjusted for age groups. Likelihood ratio test for interaction of age with time trend < 0,05 for all countries.
95% CI = 95% confidence interval
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1case of Costa Rica, or show smaller, inconsistent and
not statistically significant declines like in the remaining
countries. On the contrary, in Colombia, Venezuela and
Mexico the HIV mortality rates increased for both men
and women (p < 0.000), after ART public provision
(Table 2).
In relation with the ART coverage, those countries
with high percentage of coverage (more than 70%) had a
better HIV mortality outcome. On the contrary, those
counties with lower coverage present an increment in
their mortality trend (Tables 1, 2 and 3). However Uru-
guay, with an increasing mortality trend had a high
ART coverage (95% in 2004).
Mortality and age
F o ra l lc o u n t r i e s ,t h eh i g h e s tm o r t a l i t yr a t eb ya g eo v e r
the period was observed in the 25-44-years age group
(p < 0.01)(data not shown). The estimated mean age at
death increased over the study period around 2 to 8
years in all countries (p < 0.05), except in Ecuador
where an increase in mean age at death occurred only
among women. Statistical differences in mean age at
death before and after public provision of ART
appeared for all countries where mortality data was
available (Chile, Colombia, El Salvador, Mexico,
Panama, Venezuela) (p < 0.05), with the exception of
Ecuador. Mean age at death was consistently lower for
women over the period except in Chile and Costa Rica
(p < 0.05) (Figure 3).
Discussion
This is the first article to present population trends in
HIV mortality across selected Latin American countries.
Results suggest that six out of the eleven countries
examined show a decline in HIV mortality after the
initiation of national policies providing free public-sector
access to ART. The analysis also illustrates how men
and women are affected and vulnerable with regards to
HIV: adult men had consistently higher mortality due to
HIV while women showed less improvement in rates
over time and lower mean age at death.
The shift in mean age at HIV death, as measured in
our data, ranged from 2 to 8 years. Many factors,
including changes during the study period in HIV inci-
dence overall and among specific age groups, an
increase in HIV incidence among older adults [41-43],
increase in life expectancy among HIV patients, access
to and quality of ART, and patients’ perceptions of ART
availability and effectiveness, are likely to have influ-
enced mortality rates during the period examined by
this analysis. Our finding that introduction of national
policies for public ART provision coincided with an
increase in the mean age of death from 2 to 8 years
requires further investigation to better understand the
underlying factors. Among many possible explanations,
an increase in survival of HIV-infected patients may be
r e l a t e dt oi m p r o v e da c c e s sa n dq u a l i t yo fA R Ta n di n
the management and prophylaxis of opportunistic infec-
tions, as previously demonstrated in several cohort stu-
dies [44-46].
Mortality rates in this study were calculated relative to
the census population so that observed changes may
capture not only improvements in ART but also changes
in epidemic dynamics. For example, decreasing HIV
incidence with all other factors stable could, in theory,
lead to mortality declines. However, estimated HIV
cases and ART treatment caseloads increased, rather
than decreased, in all countries included in this analysis
during the period [13,47]. Similarly, an increase in the
age distribution of incident cases could theoretically
explain the increase in age of death observed in this
study. Yet, this is unlikely to be the case as younger
individuals continue to comprise the majority of
reported HIV and AIDS cases [47].
The consistently elevated levels of mortality among
men compared to women is most likely explained by
the fact that men who have sex with men (MSM) con-
tinue to be one of the populations with the highest pre-
valence throughout Latin America [48]; and may also
reflect prevalent gender norms, socioeconomic roles and
structures that translate to gender inequities in access to
timely diagnosis and treatment in Latin America, includ-
ing homophobia and machismo [49,50].
Differentials in access to HIV services between men
and women could contribute to differences in mortality,
however the direction of this effect is unclear. Some stu-
dies in Latin America have found that women tend to
Table 3 Age-Adjusted HIV mortality rate ratios 1996-2007
among countries with no significant difference in time
trend by sex
Year Chile Ecuador Panama Uruguay
1996 ————
1997 0.74 (0.65-0.84) 0.36 (0.30-0.44) — 1.00
1998 0.69 (0.61-0.79) 0.43 (0.36-0.51) 0.89 (0.78-1.02) 1.13 (0.85-1.50)
1999 0.86 (0.76-0.97) 0.55 (0.47-0.64) 0.98 (0.86-1.11) 1.21 (0.92-1.6)
2000 0.83 (0.73-0.94) 0.58 (0.50-0.68) 1.02 (0.90-1.16) 1.39 (1.10-1.80)
2001 1.00 0.85 (0.73-0.97) 1.00 1.55 (1.20-2.00)
2002 0.80 (0.70-0.90) 0.95 (0.82-1.10) 1.00 (0.88-1.13) —
2003 0.77 (0.68-0.87) 1.00 0.89 (0.78-1.02) 1.63 (1.27-2.11)
2004 0.72 (0.64-0.82) 1.17 (1.03-1.34) 0.92 (0.81-1.05) 1.51 (1.17-1.95)
2005 0.71 (0.62-0.80) 1.46 (1.30-1.70) ——
2006 0.76 (0.67-0.86) 1.65 (1.46-1.86) ——
HIV mortality rate ratios are calculated relative to the year of commencement
of large-scale public provision of ART
Countries present in this table do not have statistically significant interactions
among sex and year for HIV mortality rates.
Alonso Gonzalez et al. BMC Public Health 2011, 11:605
http://www.biomedcentral.com/1471-2458/11/605
Page 7 of 11start ART with higher CD4 counts than men, which
could be attributed to the scale-up of HIV screening in
pregnant women as an entry point to HIV care and
treatment. This delay in the HIV detection in the male
group could partially explain a higher HIV related mor-
tality. On the other hand, socioeconomic disparities may
affect women’s ability to access adequate HIV treat-
ments and services more than men both in the US and
Figure 3 Mean age at death, due to HIV, by sex, 1996-2007.
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Page 8 of 11LA [51-53]. Our findings concurred with these previous
publications.
The reduction in HIV mortality rates in the popula-
tion appears remarkable. This begs the question of how,
and how much, HIV mortality could be reduced further?
In the United States, the age-adjusted HIV death rate
fell by 28% from 1995 to 1996, by 46% from 1996 to
1997, and by 18% from 1997 to 1998. After 1998, the
rate leveled off at around 5 per 100,000, which is similar
to the level reported in Brazil, Argentina and Costa Rica
for the same period [54,55]. Other factors also affect
H I Vm o r t a l i t ys u c ha st h eu n relenting occurrence of
new infections, lagging ART coverage in some areas,
late presentation for HIV care with delayed ART uptake,
suboptimal treatment and adherence and lack of treat-
ment options [56]. Specific age, sex and gender identity
subgroups may still be experiencing higher HIV mortal-
ity even within countries that have substantially lowered
their rates. At the regional level this information is not
available to conduct more in-depth analysis. National
institutions, particularly those where mortality has
remained stable or increased, should engage in opera-
tional research to identify lost opportunities in the
response effort and address inequities in services’ access
that further reduce HIV mortality.
ART coverage and rate of scale-up, which were not
captured in the models, differed among countries and
were likely to influence HIV mortality trends. ART cov-
erage may have been too low in some countries to
reduce HIV mortality levels. This may be the case in
Ecuador where ART scale-up was limited until 2006,
when international funds became available [57,58].
Moreover, the rise in HIV mortality seen in some
countries may have resulted from a gap in primary and
secondary prevention and including late HIV testing and
diagnosis, low adherence and issues in treatment quality
despite relatively high ART coverage [13,16,46].
An effective universal ART coverage is one goal for
controlling the HIV/AIDS epidemic. The introduction
of policies that make the access of ART universal and
free are key to fulfill this goal, but in reality their cover-
age varied greatly among the different countries.
Furthermore, there are countries with low coverage and
this issue could explain the mortality trends differences
found in the study.
The principal limitations of the study are associated
with the source and quality of the data. Errors in regis-
tered mortality could occur during data reporting collec-
tion and processing as well as by limitations in medical
knowledge, diagnostic errors and deficiencies in the
death certification. The validity of the distribution by
cause is also affected by under reporting of deaths and
cause of death certification, even when conducted by
physicians. In many Latin American countries,
registration of death is not performed by physicians,
particularly in remote and rural areas, which can com-
promise the accuracy of cause of death classification.
Physicians may also prefer certain kinds of diagnoses,
introducing biases that may vary from country to coun-
try and over time [59]. In addition, legal and societal
concerns may lead to the underreporting of causes of a
sensitive nature, such as HIV, on the death certificate
[59]. Another limitation of the study is the difference in
the time of follow up after public ART introduction.
Some like Brazil had 11 years of follow up while others,
like El Salvador, had only 2 years of follow up post pub-
lic ART provision.
We also expect some degree of bias due to variation
in correct HIV diagnosis and cause of death registration
over time. Tendencies to misclassify as well as intention-
ally replace the registered cause of death may change
over time. For example, opportunistic infections and
cancers may be more frequently recorded as cause of
death in lieu of HIV [7,60-62]. The degree, to which
such effects occur, however, is unclear and should be
examined further.
Conclusions
Despite limitations, vital statistics are an important
source of information to study the impact of the HIV
epidemic at the population level in Latin America and
to monitor the joint impact of response efforts. Given
potential biases, this information should be analyzed in
conjunction with other sources of data, such as HIV
case-based reporting, biological and behavioural surveil-
lance, HIV drug resistance surveillance, and coverage of
prevention and treatment services in order to adequately
monitor the epidemic and its response.
Given the differences by sex found in this study, future
assessments of the response to HIV should include a gen-
der perspective and explicitly examine sex and socioeco-
nomic disparities with respect to services, norms and
laws that may constitute barriers to service access. Simi-
larly, intervention efforts should seek to involve both
men and women as part of an equitable response [63,64].
These results provide useful information to support the
monitoring of the epidemic, informing policy and pro-
grammatic action, and to motivate efforts to improve the
effectiveness of ART implementation and uptake. Further
improvement in vital registration data and analysis are
needed to improve understanding of the behavior of the
HIV epidemic, including sex and gender differences and
resulting mortality.
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